TREATMENT OF PROGRESSIVE NEURODEGENERATIVE DISEASE WITH IBUDILAST
Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
1 - 7 . (canceled)
8 . A method of treating a subject diagnosed with a syndrome of progressive visual loss comprising administering to the subject a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof.
9 . The method of claim 8 in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least 3 months.
10 . The method of claim 8 in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least six months.
11 . The method of claim 8 in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least one year.
12 . The method of claim 8 in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least two years.
13 . The method of claim 8 in which the ibudilast or pharmaceutically acceptable salt thereof is administered at least once daily.
14 . The method of claim 8 in which the ibudilast or pharmaceutically acceptable salt thereof is administered at least twice daily.
15 . The method of claim 8 in which the ibudilast or pharmaceutically acceptable salt thereof is administered orally.
16 . The method of claim 8 in which the ibudilast or pharmaceutically acceptable salt thereof is administered parenterally, enterally, intravenously, intranasally, or sublingually.
17 . The method of claim 8 in which the ibudilast or pharmaceutically acceptable salt thereof is administered topically.
18 . The method of claim 17 , in which the ibudilast or pharmaceutically acceptable salt thereof is administered as an ointment.
19 . The method of claim 8 , in which the ibudilast or pharmaceutically acceptable salt thereof is administered through an injection.
20 . The method of claim 8 , wherein the therapeutically effective amount of ibudilast or pharmaceutically acceptable salt thereof is from about 0.1 mg to about 200 mg per day.
21 . The method of claim 8 , wherein the therapeutically effective amount of ibudilast or pharmaceutically acceptable salt thereof is from about 1 mg to about 240 mg per day.
22 . The method of claim 8 , wherein the therapeutically effective amount of ibudilast or pharmaceutically acceptable salt thereof is from about 30 mg to about 240 mg per day.
23 . The method of claim 8 , wherein the therapeutically effective amount of ibudilast or pharmaceutically acceptable salt thereof is from about 30 mg to about 180 mg per day.
24 . The method of claim 8 , in which the therapeutically effective amount of ibudilast or pharmaceutically acceptable salt thereof is selected from the group consisting of 30 mg/day, 60 mg/day, 90 mg/day, or 120 mg/day.
25 . The method of claim 8 , wherein the therapeutically effective amount is administered as a single dose or is divided into multiple dosages.
26 . The method of claim 8 , wherein the therapeutically effective amount is administered in one, two, or three doses per day.
27 . The method of claim 8 , wherein the ibudilast or a pharmaceutically acceptable salt thereof is administered as part of a combination therapy that includes one or more other therapeutic agents.
28 . The method of claim 27 , wherein the one or more other therapeutic agents is approved and known to have a utility in the syndrome of progressive visual loss.
29 . The method of claim 8 , wherein the subject is a human subject.
30 . A method of treating a subject diagnosed with a syndrome of progressive visual loss comprising administering to the subject a therapeutically effective amount of ibudilast.